In less than half a year, the cumulative maximum increase of the stock price exceeded 15 times. Covid-19 antigen detection concept Bull Stock Andon Health Co.Ltd(002432) once achieved four connected boards and set a new record on Friday, but then hit the limit in the late trading and staged the scene of “sky floor”.
On the afternoon of the 17th, Andon Health Co.Ltd(002432) disclosed the latest progress of major contracts for the daily operation of the U.S. subsidiary, and the U.S. ACC paid the company’s U.S. subsidiary totaling about RMB 2.623 billion .
As soon as this announcement came out, many investors discussed it on the Internet. Some people said that “significant benefits” and “it seems that there are still opportunities”. Others said: “not necessarily. If the performance exceeds the pre increase in the early stage, can it be increased?”.
It is worth mentioning that it was in November last year that Andon Health Co.Ltd(002432) announced that the covid-19 antigen home self-test OTC Kit launched by the U.S. subsidiary was urgently authorized by the U.S. FDA and EUA , becoming the first manufacturer of home self-test kit recognized in the United States.
Subsequently, the company announced on January 13 and January 27 that the U.S. subsidiary signed the original purchase contract and change contract with ACC, purchasing 354 million ihealth kit products, with a total contract amount of USD 1.775 billion, about RMB 11.2 billion .
The announcement shows that since receiving the first batch of payment in February, ACC has paid a total of about RMB 9.715 billion . Based on this calculation, the company has received about 87% of the total purchase price of order . However, the amount of this time decreased significantly , compared with the previous payment of 4.096 billion yuan by ACC in the United States.
In terms of goods, the US subsidiary has fulfilled the delivery obligation of the contract on March 11.
On April 12, Andon Health Co.Ltd(002432) released the performance forecast. It is estimated that the net profit in the first quarter will be 14-16 billion yuan, with a year-on-year increase of 3670743% – 4196563% . Among the listed companies that have disclosed the performance forecast of the first quarter at present, ranks first in the list of pre increase .
It is calculated that the net profit of Andon Health Co.Ltd(002432) Q4 in 2021 is 863 million yuan, about 17 times of the total net profit of the first three quarters , and has exceeded the total profit since 2009 .
For the reasons for the sharp increase in performance last year and the first quarter, the company said that it mainly came from company ihealth US subsidiary . Affected by the epidemic, the sales revenue of the product increased significantly, which brought about the synchronous growth of corresponding profits.
For the current market situation, on Wal Mart’s official website, most of the kits, including ihealth, show “out of stock” status. At the same time, several media reported that Andon Health Co.Ltd(002432) for the orders of the US government, it is in a “rush” state.
Sinolink Securities Co.Ltd(600109) Yuan Wei said in the Research Report on January 17 that antigen detection can be used as direct evidence of early infection, and has the advantages of simple operation and short reporting time. In the short term, as the global epidemic continues, overseas demand for covid-19 antigen detection reagent is strong ; In the medium and long term, the demand for epidemic prevention and control continues, and the market may have a new understanding of the long-term valuation level of covid-19 detection sector in the future, high-quality enterprises are expected to seize the opportunity to open up long-term growth space .
Some market participants pointed out that from the technical level, the technical barriers of nucleic acid detection are not high, and “antigen” detection and PCR fluorescence method are relatively mature. The real barrier of the kit is mainly the time cost of government access which is stricter than other certifications. However, what can be predicted in the later stage is that there will be more and more brands of household testing kits approved by the US FDA, and the competition of international kits will become more and more fierce .
Sinolink Securities Co.Ltd(600109) research report shows that as of January 17, 13 home self-test antigen products in the U.S. market have been approved .
Yuan Wei also suggested that there was a risk of deterioration of the competition pattern of industry in the later stage. With the increase of new entrants in the industry, the original stable level of the market may be broken
10x big bull shares Andon Health Co.Ltd(002432) overseas orders have been received successively, and the subsidiaries have received nearly 10 billion in total
Andon Health Co.Ltd(002432) : American ACC paid a total of US $411 million to its American subsidiary
